Meta analysis using the most serious outcome reported shows 0% [-9‑9%] lower risk, without reaching statistical significance. 4 studies from 4 independent teams in 4 countries show significant benefit.
Control Ibuprofen
Concerns have been raised over potential harm with the use of ibuprofen for COVID-191 due to the suppression of beneficial immune and inflammatory responses during early infection, ACE2 upregulation, and delaying further care. There is limited clinical data currently, especially with regard to acute usage at onset of infection, however current results suggest harm with early treatment and benefit with late treatment.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., May 2025, preprint, 1 author.
